4.5 Article

2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative

Journal

ARTHRITIS & RHEUMATOLOGY
Volume 69, Issue 5, Pages 911-923

Publisher

WILEY
DOI: 10.1002/art.40060

Keywords

-

Categories

Funding

  1. American College of Rheumatology
  2. European League Against Rheumatism
  3. NIH (National Institute of Environmental Health Sciences [NIEHS])
  4. NIH (National Center for Advancing Translational Sciences)
  5. NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases)
  6. Istituto G. Gaslini
  7. Paediatric Rheumatology International Trials Organisation (PRINTO)
  8. Cure JM Foundation
  9. Myositis UK
  10. Myositis Association
  11. Ministry of Health, Czech Republic (Institute of Rheumatology project for conceptual development of a research organization) [00023728]
  12. MRC [MR/N003322/1] Funding Source: UKRI
  13. Medical Research Council [MR/N003322/1] Funding Source: researchfish
  14. National Institute for Health Research [CL-2006-06-010] Funding Source: researchfish
  15. ReumaFonds [LLP-10] Funding Source: researchfish

Ask authors/readers for more resources

Objective. To develop response criteria for juvenile dermatomyositis (DM). Methods. We analyzed the performance of 312 definitions that used core set measures from either the International Myositis Assessment and Clinical Studies Group (IMACS) or the Paediatric Rheumatology International Trials Organisation (PRINTO) and were derived from natural history data and a conjoint analysis survey. They were further validated using data from the PRINTO trial of prednisone alone compared to prednisone with methotrexate or cyclosporine and the Rituximab in Myositis (RIM) trial. At a consensus conference, experts considered 14 top candidate criteria based on their performance characteristics and clinical face validity, using nominal group technique. Results. Consensus was reached for a conjoint analysis-based continuous model with a total improvement score of 0-100, using absolute percent change in core set measures of minimal (>= 30), moderate (>= 45), and major (>= 70) improvement. The same criteria were chosen for adult DM/polymyositis, with differing thresholds for improvement. The sensitivity and specificity were 89% and 91-98% for minimal improvement, 92-94% and 94-99% for moderate improvement, and 91-98% and 85-86% for major improvement, respectively, in juvenile DM patient cohorts using the IMACS and PRINTO core set measures. These criteria were validated in the PRINTO trial for differentiating between treatment arms for minimal and moderate improvement (P=0.009-0.057) and in the RIM trial for significantly differentiating the physician's rating for improvement (P<0.006). Conclusion. The response criteria for juvenile DM consisted of a conjoint analysis-based model using a continuous improvement score based on absolute percent change in core set measures, with thresholds for minimal, moderate, and major improvement.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available